Shuangcheng Pharmaceuticals Seeks 52 Million Yuan Compensation in Business Trust Dispute With Zhongrong International Trust

MT Newswires Live08-06

Hainan Shuangcheng Pharmaceuticals (SHE:002693) is seeking compensation worth almost 52 million yuan in its lawsuit against Zhongrong International Trust over a business trust dispute, according to a Shenzhen bourse filing on Wednesday.

The Chinese pharmaceutical company purchased financial products totaling 50 million yuan from Zhongrong International Trust in 2022 and 2023. The products have been defaulted, but only the partial interest was paid to the company.

The amount the company seeks includes 21.1 million yuan in trust proceeds from the B859 Trust Unit and 30.9 million yuan from the A36 Trust Unit.

The company's shares dropped over 4% at the close of Wednesday's trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment